Blocking the CD96−CD155 interaction restores NK cell immunity to tumor by reversing NK cell depletion or TGF-β1 reversing NK cell depletion, suggesting that CD96 may have a therapeutic role in HCC. This evidence concerns the gene TGFB1 and neoplasm.